Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 2/20 | 0.32 |
| ▸ | PGK2 | P07205 | 2/20 | 0.32 |
| ▸ | KLK8 | O60259 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | KLK2 | P20151 | 1/20 | 0.32 |
| ▸ | KLK4 | Q9Y5K2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22750793 | 0.79 | PTK2 (0.34) | KLK8PLAUKLK2KLK4 | |
| SCHEMBL6951625 | 0.79 | TRPA1 (0.36) | PGK1PGK2KLK8PLAUKLK2 | |
| SCHEMBL18526934 | 0.78 | HPGD (0.48) | KLK8PLAUKLK2KLK4 | |
| SCHEMBL5488518 | 0.75 | — | — | |
| SCHEMBL3736933 | 0.75 | CA2 (0.48) | — | |
| SCHEMBL330066 | 0.72 | FFAR1 (0.52) | — | |
| SCHEMBL6518047 | 0.71 | PGK1 (0.55) | PGK1PGK2 | |
| SCHEMBL4901539 | 0.71 | MCHR1 (0.33) | — | |
| SCHEMBL7578789 | 0.70 | CYP4F2 (0.34) | — | |
| SCHEMBL2037665 | 0.66 | KLK8 (0.36) | PGK1PGK2KLK8PLAUKLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786421-A2 | OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES | Cengent Therapeutics, Inc. (US) | 2007-05-23 | — | — | EP | claimed |
| US-20060135483-A1 | Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2006-06-22 | — | — | US | claimed |
| WO-2006017124-A2 | OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-02-16 | — | — | WO | claimed |
| EP-1786421-A2 | OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES | Cengent Therapeutics, Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060135483-A1 | Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006017124-A2 | OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135483-A1 | Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases | PTPRO, PTPRG, PTPN1 | PGK1 515/4885PGK2 497/4885KLK8 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.